



11-05-02

ATTACHED 11/13/02 \$

Docket No: AM100012OX1  
PatentIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: MARK, R.T. et al.  
Serial No.: 09/425,501      Group Art No.: 1637  
Filed: October 22, 1999      Examiner: Suryaprabha Chunduru  
For: PABLO, A POLYPEPTIDE THAT INTERACTS WITH BCL-XL  
AND USES RELATED THERETO  
Confirmation No.: 9642  
Customer Number: 25291

**RECEIVED**

NOV 0 8 2002

Commissioner for Patents  
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

AMENDMENT TRANSMITTAL LETTER

1. Transmitted herewith for filing is an amendment for this application.

PETITION FOR EXTENSION OF TIME

2. (a) Applicant petitions for an extension of the time for the total number of months checked below:

<input type="checkbox"/>	One Month.	Fee in the amount of	\$	110.00
<input type="checkbox"/>	Two Months.	Fee in the amount of	\$	400.00
<input checked="" type="checkbox"/>	Three Months.	Fee in the amount of	\$	920.00
<input type="checkbox"/>	Four Months.	Fee in the amount of	\$	1,440.00
<input type="checkbox"/>	Five Months.	Fee in the amount of	\$	1,960.00

**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL 95385302 US addressed to the Commissioner for Patents, Washington, DC 20231.

11/4/02  
Date*Elizabeth Ruzich*  
Elizabeth Ruzich

If an additional extension of time is required, please consider this a petition therefor.

(Check and complete the next item, if applicable)

- ☐ An extension for \_\_\_\_\_ month(s) has already been secured and the fee paid therefor of \$0.00 is deducted from the total fee due for the total months of extension now requested.

OR

- (b) ☐ Applicant believes that no extension of time is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

**Extension fee due with this request: \$920.00**

FEE FOR CLAIMS


3. The fee for claims has been calculated as shown below:

CLAIMS AS AMENDED					
(1)  FOR	(2)  CLAIMS REMAINING AFTER AMENDMENT	(3)  HIGHEST NUMBER PAID FOR	(4)  NUMBER EXTRA x RATE		(5)  ADDITIONAL FEE
TOTAL CLAIMS	19	15	4	X \$ 18.00	72.00
INDEPENDENT CLAIMS	9	6	3	X \$ 84.00	252.00
MULTIPLE DEPENDENCY FEE				\$ 280.00	
				<b>Total Amendment Fee:</b>	<b>\$324.00</b>

- ☐ No additional fee for claims is required.  
☒ Total additional fee for claims required: \$324.00.

4. Method of Payment of Fees:  
Charge Deposit Account No. 07-1060 in the amount of: \$1244.00.  
**A duplicate of this transmittal is attached.**
5. Instructions as to Overpayment:  
Credit any overpayment to Deposit Account No. 07-1060.
6. Authorization to Charge Additional Fees  
☒ If any additional extension and/or fee for claims is required, charge  
Account No. 07-1060.

Respectfully submitted,



---

Gavin T. Bogle  
Attorney for Applicants  
Limited Recognition Under 37 C.F.R. §10.9(b)

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (617) 665-8079



Docket No: AM 100012 OX1

#22/D38  
11/13/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: MARK, R.T. et al.

Serial No.: 09/425,501

Group No.: 1637

Filed: October 22, 1999

Examiner: Suryaprabha Chunduru

For: PABLO, A POLYPEPTIDE THAT INTERACTS WITH BCL-XL AND USES RELATED THERETO

Confirmation No.: 9642

Customer Number: 25291

RECEIVED

NOV 08 2002

Commissioner for Patents  
Washington, DC 20231

TECH CENTER 1600/2900

Dear Sir:

This Amendment and Response is timely filed as it is accompanied by A Petition for Extension of Time Pursuant to 37 C.F.R. 1.136(a) requesting a three month extension.

AMENDMENT

Please amend the claims as follows:

49. (amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated human Bcl-xL binding protein, wherein said isolated human Bcl-xL binding protein has 98% amino acid sequence identity with a Bcl-xL binding protein set forth in SEQ ID NO:2.

D1 50. (amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated human Bcl-xL binding protein, wherein said nucleotide sequence hybridizes to the complement of a nucleotide sequence set forth in SEQ ID NO:1 which encodes a Bcl-xL binding protein in 6X SSC at 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C.

51. (amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated human Bcl-xL binding protein as shown in SEQ ID NO:1.

52. (amended) A nucleic acid molecule comprising a nucleotide sequence encoding an isolated human Bcl-xL binding domain, wherein said domain is a fragment of the nucleic acid molecule as shown in SEQ ID NO:1.

54. (amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated human Bcl-xL binding protein, wherein said isolated human Bcl-xL binding protein modulates apoptosis.

D2 55. (amended) The isolated nucleic acid molecule of claim 50, wherein said isolated human Bcl-xL binding protein modulates apoptosis.

56. (amended) The isolated nucleic acid molecule of claim 51, wherein said isolated human Bcl-xL binding protein modulates apoptosis.